On May 22, 2018, the U.S. House of Representatives passed Senate Bill 204, commonly known as the “Right to Try Act of 2017” by a vote of 250-169. The bill gives certain patients with life-threatening conditions the right to seek treatment with investigational drugs that are still in clinical trials, while bypassing the food and Drug Administration’s (FDA or the Agency) existing requirements for the Expanded Access program as well as other clinical trial regulations. The legislation has been sent to President Trump, who is expected to sign it.